Usefulness of tissue polypeptide antigen in the follow-up of XXXX .

@entity5 @entity1 @entity150 @entity865
OBJECTIVES: To evaluate the sensitivity and specificity of serum tissue polypeptide antigen ( @entity865 ) as a @entity5 marker for monitoring @entity5 recurrence in a prospective Phase II study. METHODS: This study consisted of 421 subjects allocated to three groups: 241 @entity1 treated for @entity150 between 1991 and 1995, 126 subjects with a previous history of @entity150 but with no recurrence at the time of study enrollment, and 54 healthy volunteers. Soluble @entity865 concentrations were measured by radioimmunoassay. RESULTS: On the basis of receiver operating characteristic plot analysis, the normal test threshold was set at 63 U/L. For @entity150 detection, the @entity865 specificity was 73% and sensitivity was 45%. @entity865 levels correlated with @entity5 stage (P <0.01), histologic grade, nodal stage, and metastatic stage and with urinary cytology in univariate analysis. In the subsets of @entity1 with a history of @entity150 and normal @entity865 levels, 34.9% experienced a relapse compared with 37.5% of @entity1 with elevated @entity865 levels (no statistically significant difference). Among the @entity1 with normal @entity865 levels who experienced recurrence, the mean disease-free interval was 30.6 months compared with 25.1 months in @entity1 with elevated @entity865 levels (no statistically significant difference). Multivariate analysis showed that @entity865 was not an independent prognostic biomarker for @entity5 relapse. CONCLUSIONS: In @entity1 with @entity150 , the @entity865 serum level correlated with @entity5 stage and grade, but it was not useful for detecting or monitoring relapses.
